You are here

Article Text

Article menu

Download PDFPDF

Poster Presentations
PS02 – POSTER VIEWING SESSION – TUESDAY
Tuesday, July 16, 2019 5:45 PM – 7:00 PM
P606 Oh MG! the symptoms of mycoplasma genitalium in women
Free
  1. Rosie Latimer1,
  2. Lenka Vodstrcil1,
  3. Tim Read1,
  4. Michelle Doyle2,
  5. Christopher Fairley2,
  6. Gerald Murray3,
  7. Kaveesha Bodiyabadu3,
  8. Marti Kaiser2,
  9. Jennifer Danielewski3,
  10. Elisa Mokany4,
  11. Litty Tan4,
  12. Eric Chow2,
  13. Suzanne Garland3,
  14. Catriona Bradshaw2
  1. 1Monash University, Central Clinical School, Carlton, Australia
  2. 2Alfred Health, Melbourne Sexual Health Centre, Carlton, Australia
  3. 3The Royal Women’s Hospital, Centre for Women’s Infectious Disease Research, Parkville, Australia
  4. 4SpeeDx Pty Ltd., Sydney, Australia

Abstract

Background While the contribution of Mycoplasma genitalium (MG) to symptoms in men is well described, less is known about its clinical presentation in women. Data support an association with cervicitis, but an association with pelvic inflammatory disease is contentious. We undertook a study of 1200 symptomatic and asymptomatic women to determine the prevalence of MG and macrolide resistance, and to determine its association with common genital symptoms in women to inform indications for testing.

Methods Women attending Melbourne Sexual Health Centre from 18th April 2017 (in progress) were tested for MG and macrolide resistance (ResistancePlusMG SpeeDx, Sydney), chlamydia and gonorrhoea (Aptima Combo 2, Hologic), trichomonasis (microscopy and culture), bacterial vaginosis (BV) and candida (microscopy). Women underwent examination and completed a questionnaire on symptoms. The prevalence of MG, macrolide-resistance, STIs and coinfection, and association with genital symptoms and signs, was determined by univariate and multivariable analysis.

Results Of 1054 women enrolled to date (968 symptomatic and 86 asymptomatic), 62 women (6%, 95%CI 5–7%) tested positive for MG, with macrolide-resistance detected in 54% (95%CI 41–67%). Chlamydia and gonorrhoea were detected in 8% (95%CI 6–9%) and 1% (95%CI 1–2%) of the 1054 women respectively. Of the 62 women infected with MG, 42% (95%CI 30–55) also had BV, 26% (95%CI 16–38) candida, 6% (95%CI 2–16) chlamydia and 2% (95%CI 0–9) gonorrhoea. MG prevalence did not differ between symptomatic and asymptomatic women (6% vs 5%, p=0.614). No specific genital symptoms or signs were significantly associated with MG, in contrast to chlamydia, which was associated with post-coital bleeding (OR 1.7, p=0.04) and cervicitis (OR 2.3, p=0.014).

Conclusion MG was as common as chlamydia in our clinic population but in contrast to chlamydia was not associated with any specific clinical features that would inform testing practices. Macrolide resistance was detected in half of cases and coinfection with BV was particularly common.

Disclosure No significant relationships.

  • Mycoplasma genitalium

https://doi.org/10.1136/sextrans-2019-sti.674

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.